Clinical Study on Adjuvant Treatment of Coronary Heart Disease Angina Pectoris With Chinese Patent Medicine

Last updated: July 16, 2019
Sponsor: Tianjin University of Traditional Chinese Medicine
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Thrombosis

Heart Disease

Myocardial Ischemia

Treatment

N/A

Clinical Study ID

NCT04022031
CSCD-TCM
  • Ages 35-75
  • All Genders

Study Summary

A prospective cohort study was performed in patients with angina pectoris who were treated with oral Chinese patent medicine and Western medicine.Collect primary and secondary efficacy indicators such as the incidence of cardiovascular events, using clinical samples to detect genomics, proteomics, metabolomics, intestinal flora and sclerotia.To explore the clinical efficacy of Chinese patent medicine in the treatment of coronary heart disease with angina pectoris, and provide reliable data support for its clinical application.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Voluntarily participate, understand and sign the informed consent form;

  2. Age 35-75 years old, gender is not limited;

  3. Patients with coronary heart disease and angina pectoris in the Department ofCardiology or Outpatient Department, the diagnosis of angina pectoris meets thediagnostic criteria of Western medicine and the standard of TCM syndromedifferentiation;

  4. Patients who met the criteria for drug treatment, the exposed group was treated withtraditional Chinese medicine combined with Western medicine, and the non-exposed groupwas treated with Western medicine alone.

Exclusion

Exclusion Criteria:

  1. Combined with other heart diseases, neurosis, menopausal syndrome, hyperthyroidism,cervical or vertebral artery type cervical spondylosis, gastro-oesophageal refluxdisease or esophageal hiatus hernia may cause chest pain;

  2. Patients with severe symptoms and uncontrollable angina pectoris, with acutemyocardial infarction, heart failure, myocarditis, cardiomyopathy, severe heart valvedisease, liver failure or renal failure, malignant tumors and serious metabolicdiseases;

  3. Pregnant women, lactating women or women of childbearing age who have birthrequirements;

  4. Mental patients, or cognitive dysfunction;

  5. Participated in other clinical trials in the last 3 months;

  6. Allergic persons, or those known to be allergic to therapeutic drugs;

  7. It is expected that the compliance is poor and it is not possible to visit regularly;

  8. Patients who do not have a current address or whose current address is incomplete andhave no contact number;

  9. The investigator believes that there are other situations that are not suitable forthe trial.

Study Design

Total Participants: 12400
Study Start date:
September 01, 2019
Estimated Completion Date:
September 01, 2022

Connect with a study center

  • Tianjin University of Traditional Chinese Medicine

    Tianjin, Tianjin 300193
    China

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.